{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-014489","form_type":"8-K/A","ticker":"ATYR","cik":"0001339970","company_name":"aTYR PHARMA INC","filed_at":"2022-04-14T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.313089+00:00","generated_at":"2026-06-26T07:19:41.175582+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"FDA grants orphan drug designation to aTyr Pharma's efzofitimod for systemic sclerosis","bullets":["FDA granted orphan drug designation for efzofitimod to treat systemic sclerosis (scleroderma) on April 12, 2022.","Orphan designation may provide 7-year market exclusivity, tax credits, and waiver of FDA fees.","Efzofitimod is aTyr's lead therapeutic candidate; this designation supports its development program."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-014489","json":"https://secwatch.observer/filing/0001564590-22-014489.json","markdown":"https://secwatch.observer/filing/0001564590-22-014489.md","text":"https://secwatch.observer/filing/0001564590-22-014489.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339970/000156459022014489/0001564590-22-014489-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339970/000156459022014489/life-8ka_20220412.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T07:19:41.175582+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}